(Q)-Twist analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer

被引：0
|
作者：
Chung, H. C.
Bang, Y.
Van Cutsem, E.
Kang, Y.
Hamamoto, Y.
Moiseyenko, V.
Gotovkin, E.
Urspruch, A.
Ducournau, P.
机构：
[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[3] Univ Hosp Gasthuisberg, Dept Digest Oncol, B-3000 Louvain, Belgium
[4] Univ Ulsan Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[5] Tochigi Canc Ctr, Utsunomiya, Tochigi, Japan
[6] Inst Oncol, Dept Biotherapy & BMT, St Petersburg, Russia
[7] Ivanovo Reg Oncol Dispensary, Ivanovo, Russia
[8] F Hoffmann La Roche, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4048
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Gravalos, Cristina
    Gomez-Martin, Carlos
    Rivera, Fernando
    Ales, Inmaculada
    Queralt, Bernardo
    Marquez, Antonia
    Jimenez, Ulpiano
    Alonso, Vicente
    Garcia-Carbonero, Rocio
    Sastre, Javier
    Colomer, Ramon
    Cortes-Funes, Hernan
    Jimeno, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (03): : 179 - 184
  • [2] Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer
    Cristina Grávalos
    Carlos Gómez-Martín
    Fernando Rivera
    Inmaculada Alés
    Bernardo Queralt
    Antonia Márquez
    Ulpiano Jiménez
    Vicente Alonso
    Rocío García-Carbonero
    Javier Sastre
    Ramon Colomer
    Hernán Cortés-Funes
    Antonio Jimeno
    Clinical and Translational Oncology, 2011, 13
  • [3] First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
    Chung, Hyun Cheol
    Bang, Yung-Jue
    S Fuchs, Charles
    Qin, Shu-Kui
    Satoh, Taroh
    Shitara, Kohei
    Tabernero, Josep
    van Cutsem, Eric
    Alsina, Maria
    Cao, Zhu Alexander
    Lu, Jia
    Bhagia, Pooja
    Shih, Chie-Schin
    Janjigian, Yelena Y.
    FUTURE ONCOLOGY, 2021, 17 (05) : 491 - 501
  • [4] FIRST-LINE TREATMENT IN HER2-POSITIVE ADVANCED OR METASTATIC GASTRIC CANCER
    Yamaguchi, K.
    Ooki, A.
    Yamada, T.
    Hara, H.
    Asayama, M.
    Tada, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
  • [5] A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients
    Zhu, Bo
    Wu, Jun-Rong
    Zhou, Xiao-Ping
    MEDICINE, 2015, 94 (34) : e1428
  • [6] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [7] First-line pyrotinib plus trastuzumab and nab-paclitaxel for patients with HER2-positive advanced breast cancer
    Xie, Hui
    Li, Wei
    Yao, Yufeng
    Ni, Sujie
    Yi, Tongbo
    Cheng, Jinling
    Fang, Qi
    Zhang, Lei
    Zhou, Jun
    Wu, Xiaohong
    Wang, Chunbin
    Zhang, Yanan
    Qin, Jianwei
    Shao, Qing
    Zhao, Tao
    Huang, Xiaohong
    Xu, Lingyun
    CANCER RESEARCH, 2022, 82 (04)
  • [8] Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
    Kazuhiro Nishikawa
    Hisato Kawakami
    Toshio Shimokawa
    Kazumasa Fujitani
    Shigeyuki Tamura
    Shunji Endo
    Michiya Kobayashi
    Junji Kawada
    Yukinori Kurokawa
    Akira Tsuburaya
    Takaki Yoshikawa
    Junichi Sakamoto
    Taroh Satoh
    International Journal of Clinical Oncology, 2023, 28 : 1501 - 1510
  • [9] Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer
    Nishikawa, Kazuhiro
    Kawakami, Hisato
    Shimokawa, Toshio
    Fujitani, Kazumasa
    Tamura, Shigeyuki
    Endo, Shunji
    Kobayashi, Michiya
    Kawada, Junji
    Kurokawa, Yukinori
    Tsuburaya, Akira
    Yoshikawa, Takaki
    Sakamoto, Junichi
    Satoh, Taroh
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (11) : 1501 - 1510
  • [10] A RETROSPECTIVE ANALYSIS OF FIRST-LINE TREATMENT IN HER2-POSITIVE AND HER2-NEGATIVE ADVANCED GASTRIC CANCER
    Onodera, K.
    Kawakami, K.
    Yukisawa, S.
    Warita, E.
    Yamanaka, Y.
    ANNALS OF ONCOLOGY, 2013, 24 : 68 - 68
12345